Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17891681 | 0.95 | AKT1 (0.60) | PDPK1CYTH3AKT1MAPTNPC1 | |
| SCHEMBL17897750 | 0.83 | PDPK1 (0.71) | PDPK1CYTH3AKT1MAPTNPC1 | |
| SCHEMBL17897761 | 0.81 | AKT1 (0.85) | PDPK1CYTH3AKT1MAPTNPC1 | |
| SCHEMBL17897747 | 0.77 | MAPT (0.68) | PDPK1CYTH3AKT1MAPTNPC1 | |
| SCHEMBL17897743 | 0.75 | AKT1 (0.64) | PDPK1CYTH3AKT1MAPTNPC1 | |
| SCHEMBL15777209 | 0.74 | AKT1 (0.83) | PDPK1CYTH3AKT1MAPTNPC1 | |
| SCHEMBL6611147 | 0.73 | HCAR3 (0.52) | MAPTNPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL17897753 | 0.73 | AKT1 (0.57) | PDPK1CYTH3AKT1MAPTNPC1 | |
| SCHEMBL17897749 | 0.72 | ALDH1A1 (0.71) | PDPK1AKT1MAPTALDH1A1LMNA | |
| SCHEMBL15777239 | 0.72 | AKT1 (0.65) | PDPK1CYTH3AKT1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160194279-A1 | ONE POT PROCESS FOR THE CONVERSION OF AROYL CHLORIDES TO ACYL THIOUREAS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-07-07 | — | — | US | disclosed |
| US-20160194279-A1 | ONE POT PROCESS FOR THE CONVERSION OF AROYL CHLORIDES TO ACYL THIOUREAS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194279-A1 | ONE POT PROCESS FOR THE CONVERSION OF AROYL CHLORIDES TO ACYL THIOUREAS | TRRAP, NAT1, AHR | PDPK1 4430/4885CYTH3 2061/4885AKT1 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.